Treating Hepatitis C in Pakistan. Strategies to Avoid Resistance to Antiviral Drugs
ConditionHepatitis C, Chronic
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18-100
SponsorQueen Mary University of London
About this trial
We will determine how best to manage the hepatitis C virus (HCV) epidemic in Pakistan by measuring effectiveness of Pakistan-government sponsored current therapies, emergence of viral resistance, consequences of infection (chiefly liver cancer) and through developing models, based on incidence data, determine the proportion of people who need curative treatment to eliminate HCV, and assess whether targeting can optimise this.
Eligibility criteria
Qualifiers
Adults over 18yrs old
Willing to undergo hepatitis C testing
Able and willing to give informed consent
Willing to return in 12 months time for repeat testing
Disqualifiers
Unwilling to give consent
Unwilling or unable to undergo the necessary procedures
Clinically significant illness (other than HCV) or other major medical condition that may interfere with the subject's treatment, assessment or compliance with protocol.
Co-morbidities limiting life expectancy to less than 12 months
Trial design
Treatments tested in this trial
- HCV RNA (PCR)
- HCV Antibody test (Point of care)
- AST/ALT and platelets measurement
Treatment groups
25,000 Participants
are divided into 4 treatment groupsSponsors and collaborators
Queen Mary University of London
Lead sponsor
Aga Khan University
Collaborator
Dow University of Health Sciences
Collaborator
University of Oxford
Collaborator
University of Bristol
Collaborator
Source ClinicalTrials.gov